Ticker
BMY

Price
74.53
Stock movement up
+0.08 (0.11%)
Company name
Bristol-Myers Squibb Company
Exchange
(NYSE
,
Currency
USD
)
Sector
Healthcare >
Drug Manufacturers-General
Market cap
158.46B
Ent value
216.19B
Price/Sales
3.39
Price/Book
4.84
Div yield
3.06%
Div growth
6.72%
Growth years
12
FCF payout
36.05%
Trailing P/E
23.73
Forward P/E
9.33
PEG
1.29
EPS growth
10.90%
1 year return
16.33%
3 year return
5.05%
5 year return
3.48%
10 year return
7.51%
Last updated: 2023-02-06

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share2.28
Dividend yield3.06%
Payout frequencyQuarterly
Maximum yield4.03%
Average yield3.09%
Minimum yield2.32%
Discount to avg yield-1.14%
Upside potential-1.12%
Yield as % of max yield75.96%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield3.06%
Current yield distribution52.30%
Yield at 100% (Min)2.32%
Yield at 90%2.72%
Yield at 80%2.85%
Yield at 50% (Median)3.07%
Yield at 20%3.33%
Yield at 10%3.52%
Yield at 0% (Max)4.03%

Dividend per share

Loading...
Dividend per share data
Years of growth12 years
CCC statusDividend Contender
Dividend per share2.28
Payout frequencyQuarterly
Ex-div date5 Jan 2023
EPS (TTM)3.11
EPS (1y forward)7.99
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
BMYS&P500
DGR MR5.56%11.59%
DGR TTM8.96%10.54%
DGR 3 years9.62%4.00%
DGR 5 years6.72%5.65%
DGR 10 years4.73%7.37%
DGR 15 years4.48%5.83%
Time since last change announced62 days
EPS growth (5y)10.90%
EPS growth (5y forward)18.40%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM68.71%36.05%
Average--
Forward28.54%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E23.73
Price to OCF11.47
Price to FCF12.45
Price to EBITDA8.63
EV to EBITDA11.77

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales3.39
Price to Book4.84
EV to Sales4.63

FINANCIALS

Per share

Loading...
Per share data
Current share count2.13B
EPS (TTM)3.11
FCF per share (TTM)5.92

Income statement

Loading...
Income statement data
Revenue (TTM)46.74B
Gross profit (TTM)36.84B
Operating income (TTM)9.77B
Net income (TTM)6.68B
EPS (TTM)3.11
EPS (1y forward)7.99

Margins

Loading...
Margins data
Gross margin (TTM)78.82%
Operating margin (TTM)20.91%
Profit margin (TTM)14.29%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash7.73B
Net receivables9.61B
Total current assets26.80B
Goodwill21.11B
Intangible assets38.18B
Property, plant and equipment0.00
Total assets98.20B
Accounts payable2.60B
Short/Current long term debt39.10B
Total current liabilities18.93B
Total liabilities65.46B
Shareholder's equity32.73B
Net tangible assets-25.54B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)13.82B
Capital expenditures (TTM)1.09B
Free cash flow (TTM)12.72B
Dividends paid (TTM)4.59B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity20.40%
Return on Assets6.80%
Return on Invested Capital9.30%
Cash Return on Invested Capital17.71%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open74.45
Daily high75.18
Daily low74.23
Daily Volume5.96M
All-time high81.13
1y analyst estimate81.57
Beta0.43
EPS (TTM)3.11
Dividend per share2.28
Ex-div date5 Jan 2023
Next earnings date27 Apr 2023

Downside potential

Loading...
Downside potential data
BMYS&P500
Current price drop from All-time high-8.14%-14.21%
Highest price drop-76.73%-56.47%
Date of highest drop16 Oct 20089 Mar 2009
Avg drop from high-34.22%-11.49%
Avg time to new high40 days13 days
Max time to new high4176 days1805 days
COMPANY DETAILS
BMY (Bristol-Myers Squibb Company) company logo
Marketcap
158.46B
Marketcap category
Large-cap
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Employees
32200
SEC filings
CEO
Giovanni Caforio
Country
USA
City
New York
Stock type
Common stock
CCC status
Dividend Contender
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Originally published on Bristol Myers Squibb News & Perspectives
February 6, 2023
Bristol-Myers Squibb & Co (NYSE: BMY) has returned the exclusive rights to Dragonfly Therapeutics' IL-12 oncology candidate. In 2020, BMS handed out $475 million in near-term and upfront payments deal...
February 6, 2023
Bristol Myers' Sotyktu recently moved one step closer to its first approval in the European Union.
February 6, 2023
Shares in pharmaceutical company Bristol Myers Squibb (NYSE: BMY) are up a little more than 11% over the past year. The company posted third-quarter revenue of $11.2 billion, a decrease of 3%, with o...
February 4, 2023
Bristol-Myers Squibb ( NYSE:BMY ) Full Year 2022 Results Key Financial Results Revenue: US$46.2b (flat on FY 2021). Net...
February 4, 2023
Companies in The news Are: META, BMY, PH, CAH.
February 3, 2023
NEW YORK, February 03, 2023--Bristol Myers Squibb to Participate in the Guggenheim Healthcare Talks 2023 Oncology Conference
February 3, 2023
Bristol's Revlimid took fewer than expected generic hits in the fourth quarter, resulting in a beat and a pop for BMY stock Thursday.
February 2, 2023
Bristol-Myers' (BMY) fourth-quarter 2022 earnings beat estimates, while sales declined year over year due to generic erosion for oncology drug Revlimid.
February 2, 2023
At this time, I would like to welcome everyone to the Bristol-Myers Squibb fourth quarter 2022 earnings conference call. Joining me this morning with prepared remarks are Giovanni Caforio, our board ...
February 2, 2023
Next page